Towa Pharmaceutical Co., Ltd. · TSE:4553

Towa Pharmaceutical — FY2007 Earnings Presentation

22 slides from Towa Pharmaceutical's earnings presentation, May 16, 2007

  1. Slide 1: FY2007 Results Presentation (4553)

    2007 3 2007 5 16 ( 4553)

  2. Slide 2: CONTENTS

    CONTENTS . 2007 3 2 . 2008 3 12 -1-

  3. Slide 3: FY March 2007 Results

    . 2007 3

  4. Slide 4: FY2007 Results Summary

    2007 3 ( %) 07/3 06/3 29,235 +20.8 24,193 13,646 46.7 +24.5 10,957 45.3 9,229 31.6 +7.8 8,560 35.4 4,416 15.1 +84.2 2,397 9.9 4,886 16.7 +39.4 3,506 14.5 2,598 8.9 +156.6 1,012 4.2 -3-

  5. Slide 5: Net Sales Change Analysis

    +139 +40 +56 06 +1,215 +766 05 +692 +5,042 +602 04 +990 29,235 03 +542 02 24,193 06/3 07/3 -4-

  6. Slide 6: ( ) (06 ) 02~05 (05 ) +110.6% (04 ) +63.1% 03 +55.3% 40

    ( ) 120 19 (06 ) 7 80 02~05 90 (05 ) 05 +110.6% (04 ) 04 +63.1% 03 +55.3% 40 02 +17.2% (03 ) (02 ) 0 04/3 05/3 06/3 07/3 -5-

  7. Slide 7: Operating Income Change Factors

    ( ) 07/3 z 4,546 322 (4,223) 1,931 151 z 05/4 (1,779) BE 647 3 (644) 2,104 183 z TVCM (1,920) 9,229 669 (8,560) -6-

  8. Slide 8: Non-operating and Extraordinary Items

    ( ) 07/3 06/3 4,416 2,397 206 564 1,168 206 789 06 3 116.47 /$ 94 58 07 3 117.05 /$ 4,886 3,506 12 54 535 1,283 2,598 1,012 -7-

  9. Slide 9: Balance Sheet

    ( ) 07/3 06/3 1,179 1,177 +2 11,801 10,513 +1,288 316 11 +304 8,215 7,020 +1,195 644 438 +206 23,378 20,036 +3,342 20,289 20,087 +201 43,668 40,124 +3,544 4,066 3,770 +296 1,334 754 +580 9,277 7,739 +1,538 1,120 1,241 120 10,397 8,980 +1,417 33,270 31,144 +2,126 43,668 40,124 +3,544 -8-

  10. Slide 10: Cash Flow

    ( ) 20 06/3 07/3 15 10 5 0 CR -9-

  11. Slide 11: Sales Composition

    ( ) 5.4% 26.5% 68.1% 07/3 4.6% 26.9% 68.4% 06/3 0 100 200 300 -10-

  12. Slide 12: Composition by Category

    ( ) 10.7% 3.2% 62.5% 23.5% 07/3 10.8% 3.8% 06/9 61.8% 23.6% 11.2% 3.5% 06/3 64.0% 21.2% 11.4% 3.8% 65.1% 19.7% 05/9 -11-

  13. Slide 13: FY March 2008 Forecast

    . 2008 3

  14. Slide 14: FY2008 Forecast

    2008 3 ( %) 08/3 ( ) 07/3 32,400 +10.8 29,235 5,600 17.3 +26.8 4,416 15.1 5,800 17.9 +18.7 4,886 16.7 3,550 11.0 +36.6 2,598 8.9 -13-

  15. Slide 15: OD D

    324 07 340 14 22 9 292 11 OD 7 29 290 06 23 1 20 16 05 240 29 38 D 02~04 38 42 190 179 174 140 07/3 08/3 -14-

  16. Slide 16: ( ) 05/3 06/3 07/3 08/3 -15-

    ( ) 40 32 30 25 25 20 13 10 0 05/3 06/3 07/3 08/3 -15-

  17. Slide 17: GMP / GE

    GMP GE -16-

  18. Slide 18: Regulatory Developments

    1. 06.3.10 23 ¾ 86 z 7 z 35 z 22 z 22 „ 18 2.3 -17-

  19. Slide 19: Regulatory Developments

    2. 06.3.10 5 3. 06.3.24 2008 3 4. 06.6.22 2006 1 -18-

  20. Slide 20: GE Market Trends

    02 04 06 08 2.7% 1.0% 3.6% GE 2 1 ? “GE ” 2 3 GE GE 30% ? -19-

  21. Slide 21: New Product Launches

    GE 06 453 07 5/10 224 100/ 198 2.5mg/5mg 1,892 08 2.5/5/10 168 100mg 416 75mg/100mg/ 09 362 100mg 50mg/100mg 210 -20-

  22. Slide 22: Contact

    TEL 06-6900-9101 FAX 06-6900-0634 -21-

Towa Pharmaceutical — FY2007 Earnings Presentation on 6ix